Sermorelin, ipamorelin, and CJC-1295 get lumped together and sold hard. This provider comparison lays out mechanism, evidence, and patient-selection logic without the pitch.
Sermorelin, ipamorelin, and CJC-1295 show up in the same patient conversations and the same clinic marketing, but they are not interchangeable, and most of what patients find online is a sales page rather than a comparison. All three are growth hormone secretagogues, meaning they stimulate the body's own GH release through physiologic signaling rather than delivering exogenous GH directly — a distinction that matters clinically because it preserves the pulsatility and feedback regulation that exogenous GH bypasses. This is a neutral, side-by-side look at how these peptides work, where they differ, and how a provider should think about selecting between them.
In this article
Mechanism
GH secretagogues work through one of two receptor pathways. GHRH-receptor agonists — sermorelin, CJC-1295, and tesamorelin — mimic growth hormone-releasing hormone and stimulate the pituitary through the same pathway the body uses naturally. Ghrelin-receptor (GHS-R1a) agonists — ipamorelin, GHRP-2, GHRP-6, and MK-677 — work through a separate receptor identified in the brain, pituitary, and pancreas, activated endogenously by ghrelin. Some formulations preserve the body's natural pulsatile GH release pattern; others, like CJC-1295 with DAC, are engineered for sustained, non-pulsatile elevation instead. That pulsatile-vs-sustained distinction is one of the more clinically relevant differences across this peptide class, and it's worth understanding before comparing individual products.
Provider Comparison
Sermorelin is a synthetic analog of the first 29 amino acids of GHRH. It acts through the GHRH receptor, preserves the pulsatile GH pattern, and drives IGF-1 downstream. Sermorelin was previously FDA-approved for pediatric growth hormone deficiency but was withdrawn from the US market in 2008; it's now compounded for off-label adult use, and the anti-aging evidence supporting that use is limited.
CJC-1295 comes in two distinct forms that behave very differently, and conflating them is a common mistake. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of roughly 30 minutes and produces a physiologic-like GH pulse. CJC-1295 with DAC binds to serum albumin via Drug Affinity Complex technology, extending its half-life to six to eight days and producing sustained, non-pulsatile GH elevation instead. Both forms are compounded and not FDA-approved, and CJC-1295 appears on FDA's list of substances with identified safety risks — immunogenicity, impurities, and limited human data — which should be part of the informed consent conversation regardless of which form is used.
Ipamorelin is a selective GHS-R1a agonist that raises GH without significantly increasing cortisol, prolactin, or ACTH, and with minimal appetite stimulation. That selectivity is what distinguishes it from older ghrelin agonists like GHRP-2 and GHRP-6. Ipamorelin is compounded, also appears on FDA's safety-risk list under ipamorelin acetate, is not on the 503A bulks list, and its compounding status remains under ongoing review — a status worth verifying against current FDA guidance rather than assuming.
Two other agents round out this category and are worth knowing where they fit. MK-677 (ibutamoren) is an orally bioavailable, non-peptide GHS-R1a agonist — not FDA-approved and generally classified as investigational. Tesamorelin (Egrifta) is a stabilized GHRH analog and, notably, the one peptide in this comparison with FDA approval, specifically for reduction of visceral fat in HIV-associated lipodystrophy. That approval does not extend to off-label body-composition use in other populations, and the evidence supporting that extrapolation is considerably thinner than the trial data behind the approved indication.
| Agent | Class / receptor | Half-life / pulse pattern | FDA status | Notable feature |
|---|---|---|---|---|
| Sermorelin | GHRH-receptor agonist | Pulsatile GH pattern | Previously FDA-approved for pediatric GH deficiency; withdrawn in 2008; compounded for off-label adult use | Synthetic analog of the first 29 amino acids of GHRH |
| Ipamorelin | Selective GHS-R1a agonist | Ghrelin-pathway agent | Compounded; FDA safety-risk list under ipamorelin acetate; not on the 503A bulks list | Minimal cortisol, prolactin, ACTH, and appetite effects |
| CJC-1295 (no DAC) | GHRH-receptor agonist | Roughly 30 minutes; physiologic-like GH pulse | Compounded; not FDA-approved; FDA safety-risk list | Also called Mod GRF 1-29 |
| CJC-1295 (DAC) | GHRH-receptor agonist | Six to eight days; sustained, non-pulsatile elevation | Compounded; not FDA-approved; FDA safety-risk list | Binds serum albumin via Drug Affinity Complex technology |
| GHRP-2 / GHRP-6 | Older ghrelin agonists | Ghrelin pathway | Not FDA-approved | Less selective; GHRP-6 produces a stronger appetite effect |
| MK-677 | Non-peptide GHS-R1a agonist | Orally bioavailable | Not FDA-approved; generally investigational | Non-peptide agent |
| Tesamorelin | Stabilized GHRH analog | GHRH pathway | FDA-approved for reduction of visceral fat in HIV-associated lipodystrophy | Approval does not extend to off-label body-composition use in other populations |
Sermorelin
GHRH-receptor agonist
Pulsatile GH pattern. Previously FDA-approved for pediatric GH deficiency; withdrawn in 2008; compounded for off-label adult use.
Notable feature: Synthetic analog of the first 29 amino acids of GHRH.
Ipamorelin
Selective GHS-R1a agonist
Compounded; FDA safety-risk list under ipamorelin acetate; not on the 503A bulks list.
Notable feature: Minimal cortisol, prolactin, ACTH, and appetite effects.
CJC-1295 (no DAC)
GHRH-receptor agonist
Roughly 30 minutes; physiologic-like GH pulse. Compounded, not FDA-approved, and on the FDA safety-risk list.
Notable feature: Also called Mod GRF 1-29.
CJC-1295 (DAC)
GHRH-receptor agonist
Six to eight days; sustained, non-pulsatile elevation. Compounded, not FDA-approved, and on the FDA safety-risk list.
Notable feature: Binds serum albumin via Drug Affinity Complex technology.
GHRP-2 / GHRP-6
Older ghrelin agonists
Ghrelin pathway; not FDA-approved.
Notable feature: Less selective; GHRP-6 produces a stronger appetite effect.
MK-677
Non-peptide GHS-R1a agonist
Orally bioavailable; not FDA-approved and generally investigational.
Tesamorelin
Stabilized GHRH analog
FDA-approved for reduction of visceral fat in HIV-associated lipodystrophy.
Notable feature: Approval does not extend to off-label body-composition use in other populations.
Getting this comparison right — mechanism, evidence tier, and regulatory status together — is the kind of cross-peptide reasoning the IAPAM peptide therapy course is built to train, rather than treating each product as a standalone sales pitch.
Combination Protocol
CJC-1295 without DAC paired with ipamorelin is the most commonly discussed GH secretagogue combination, and the rationale is straightforward: a GHRH-pathway agonist and a ghrelin-pathway agonist working through separate receptors can converge on a larger, more physiologic-like GH pulse than either produces alone. Typical protocols use roughly 100 to 300 mcg of each, given subcutaneously, 30 to 60 minutes before sleep or exercise. Human trial data for this specific combination remains limited, and providers should hold that caveat alongside the mechanistic rationale rather than let the plausibility of the combination substitute for outcome evidence. When a ghrelin-pathway agent is indicated, ipamorelin's receptor selectivity — lower cortisol, prolactin, and appetite stimulation — is generally preferred over the older, less-selective GHRP-2 and GHRP-6, with GHRP-6 in particular producing a stronger appetite effect.
Clinical Selection & Monitoring
IGF-1 is the primary monitoring marker across this entire category, and the treatment goal should be the age- and sex-adjusted reference range, not the ceiling. Supraphysiologic IGF-1 is associated with increased cancer risk, which makes "maximize IGF-1" the wrong framing for any protocol in this class. Draw IGF-1 fasting, in the morning, and interpret it against age-adjusted norms.
Dosing across this category is not standardized by regulatory approval, since these are compounded products. Start low and titrate to clinical response and IGF-1, and treat commonly used cycling patterns — three to six months on, one to two months off — as convention rather than trial-validated protocol. GH secretagogues can also reduce insulin sensitivity and raise fasting glucose, so glucose monitoring matters particularly for patients with prediabetes, diabetes, or metabolic syndrome. Across the class, rigorously controlled long-term human studies remain scarce. Clinically relevant adverse effects and limited human safety information should be part of patient counseling, and long-term safety remains unestablished.
GH Secretagogue Selection Decision Tree
GHRH pathway
Sermorelin, CJC-1295, and tesamorelin mimic growth hormone-releasing hormone and stimulate the pituitary through the same pathway the body uses naturally.
Pulsatile: sermorelin / CJC-1295 no DACSustained: CJC-1295 with DACGhrelin pathway
Ipamorelin, GHRP-2, GHRP-6, and MK-677 work through the separate GHS-R1a receptor pathway.
Selective: ipamorelinOlder: GHRP-2 / GHRP-6Evidence tier / FDA status
Tesamorelin is the one peptide in this comparison with FDA approval, specifically for reduction of visceral fat in HIV-associated lipodystrophy. CJC-1295 and ipamorelin appear on FDA's safety-risk list.
FDA-approved: tesamorelinSafety-risk list: CJC-1295 / ipamorelinApplying this level of evidence discipline consistently — instead of defaulting to whichever combination a supplier is promoting — is exactly what the IAPAM peptide therapy course trains providers to do across the GH secretagogue category.
Key Takeaways
GH secretagogues stimulate the body's own GH release rather than delivering exogenous GH, preserving pulsatility and feedback that exogenous GH bypasses.
Sermorelin and CJC-1295 (no DAC) work through the GHRH receptor with a physiologic pulse; CJC-1295 with DAC produces sustained, non-pulsatile elevation instead; ipamorelin is a selective ghrelin-receptor agonist with minimal cortisol, prolactin, and appetite effects.
Tesamorelin is the one agent in this comparison with FDA approval, and only for visceral-fat reduction in HIV-associated lipodystrophy — off-label extrapolation is not equally supported by evidence.
Target IGF-1 within the age-adjusted reference range, not the maximum; supraphysiologic IGF-1 carries increased cancer risk.
Monitor glucose and insulin sensitivity across this category, particularly in patients with prediabetes, diabetes, or metabolic syndrome, and treat cycling protocols as convention rather than validated dosing.
For the broader picture, see our peptide therapy for providers hub. Providers weighing regenerative peptides alongside GH secretagogues will find related evidence and consent considerations in our BPC-157 provider guide.
Frequently asked questions
No. GH secretagogues stimulate the body's own pituitary to release GH through physiologic signaling, whereas HGH (exogenous growth hormone) is administered directly. Secretagogues preserve the pulsatility and feedback regulation that direct HGH administration bypasses.
They work through different receptors and aren't directly interchangeable. Sermorelin is a GHRH-receptor agonist with a pulsatile pattern; ipamorelin is a selective ghrelin-receptor agonist with minimal cortisol, prolactin, and appetite effects. Which is appropriate depends on the clinical goal and the patient, not a universal ranking.
CJC-1295 without DAC has a roughly 30-minute half-life and produces a physiologic-like GH pulse. CJC-1295 with DAC binds serum albumin, extending its half-life to six to eight days and producing sustained, non-pulsatile GH elevation instead. Both are compounded, non-FDA-approved, and appear on FDA's safety-risk substance list.
The two work through separate receptor pathways — GHRH and ghrelin — that can converge on a larger, more physiologic-like GH pulse together than either alone. Human trial data for the specific combination remains limited, so the rationale is mechanistic rather than outcome-proven.
MK-677 (ibutamoren) is not FDA-approved and is generally classified as investigational. A trial in healthy older adults showed increased fat-free mass but also increased appetite, body weight, fasting glucose, and reduced insulin sensitivity, so the tradeoffs need to be part of any patient discussion.
Tesamorelin (Egrifta) is FDA-approved, specifically for reduction of visceral fat in HIV-associated lipodystrophy. Sermorelin was previously FDA-approved for pediatric GH deficiency but was withdrawn from the market in 2008 and is now used off-label as a compounded product. No other peptide in this comparison carries FDA approval.
IGF-1 is the primary monitoring marker, drawn fasting and in the morning, interpreted against age- and sex-adjusted reference ranges — the goal is the normal range, not the maximum. Fasting glucose and insulin sensitivity should also be monitored, particularly in patients with prediabetes, diabetes, or metabolic syndrome.
Go Deeper
IAPAM Peptide Therapy Course
View Training →Peptide Therapy for Providers
Back to Hub →BPC-157 Provider Guide
Read the Guide →References